Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3-ITD mutated AML patients: on behalf of the ALWP/EBMT

Hematology Division, Department of Bone Marrow Transplantation, Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Hôpital Saint-Antoine, EBMT ALWP Office, Paris, France Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK Assistance Publique-Hôpitaux de Paris, Hematology Stem Cell Transplantation, Saint Louis Hospital, Paris, France CHU de Lille, University of Lille, INSERM, U1285, Lille, France Hematology Department, Section for Stem Cell Transplantation, Oslo University Hospital, Rikshospitalet, Clinic for Cancer Medicine, Oslo, Norway HUCH Comprehensive Cancer Center, Helsinki, Finland Nottingham University, Nottingham, UK Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam, Netherlands Centre Hospitalier Lyon Sud, Pavillon Marcel Bérard, Service Hematologie, Lyon, France Stem Cell Transplant Unit, Policlinico Universitario Tor Vergata, University of Rome, Rome, Italy Hematology and Cell Therapy Department, Bordeaux University Hospital, Bordeaux, France Hematology Department, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain Hematology Division, Department of Hematology, Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Department of Haematology, Saint Antoine Hospital, INSERM UMR 938 and Sorbonne University, Paris, France